Blog

Cross-Lab Data Collaborations – The Future Of Immunotherapy? – Life Science Leader Magazine


Life Science Leader Magazine

Cross-Lab Data Collaborations – The Future Of Immunotherapy?
Life Science Leader Magazine
In the field of immunotherapy, a handful of Big Pharma companies have been racing to achieve first or second line approval of their own checkpoint inhibitors in a small set of indications, including nonsmall cell lung cancer and bladder cancer

2017-03-22 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.